ERBB2 and neoplasm: Given the plethora of HER2‐targeting therapies and tumor‐agnostic approval for trastuzumab deruxtecan, next‐generation sequencing and HER2 immunohistochemistry should be considered in cases of metastatic cSCC to identify potentially actionable mutations.